Hemogenyx Pharmaceuticals PLC Announces Placing to Raise 拢250,000 and Director's Dealing
Hemogenyx Pharmaceuticals (OTC:HOPHF) has secured 拢250,000 through a strategic share placement, issuing 133,690 new ordinary shares at 187p per share, representing a premium to the current market price. The shares will be initially allotted to CEO Vladislav Sandler, who will then transfer them to a group of new investors.
The funding will support the continuation of the company's Phase I clinical trials for HG-CT-1, their Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The company reports that the first two patients have completed four-week safety trials with encouraging early efficacy signs.
The deal includes one-for-one warrants exercisable at 187p for 36 months. Upon admission of the new shares, expected around August 7, 2025, the total number of issued shares will be 4,727,229.
Hemogenyx Pharmaceuticals (OTC:HOPHF) ha ottenuto 拢250.000 tramite un collocamento strategico di azioni, emettendo 133.690 nuove azioni ordinarie a 187p per azione, rappresentando un premio rispetto al prezzo di mercato attuale. Le azioni saranno inizialmente assegnate al CEO Vladislav Sandler, che poi le trasferir脿 a un gruppo di nuovi investitori.
I fondi sosterranno la prosecuzione degli studi clinici di Fase I per HG-CT-1, la loro terapia con cellule T a recettore antigene chimerico (CAR-T) rivolta alla leucemia mieloide acuta recidivante/refrattaria negli adulti. L'azienda riferisce che i primi due pazienti hanno completato le prove di sicurezza di quattro settimane con segnali iniziali di efficacia promettenti.
L'accordo include warrant uno a uno esercitabili a 187p per 36 mesi. Con l'ammissione delle nuove azioni, prevista intorno al 7 agosto 2025, il numero totale di azioni emesse sar脿 4.727.229.
Hemogenyx Pharmaceuticals (OTC:HOPHF) ha asegurado 拢250,000 a trav茅s de una colocaci贸n estrat茅gica de acciones, emitiendo 133,690 nuevas acciones ordinarias a 187p por acci贸n, lo que representa una prima sobre el precio actual de mercado. Las acciones ser谩n inicialmente asignadas al CEO Vladislav Sandler, quien luego las transferir谩 a un grupo de nuevos inversores.
Los fondos apoyar谩n la continuaci贸n de los ensayos cl铆nicos de Fase I para HG-CT-1, su terapia con c茅lulas T de receptor de ant铆geno quim茅rico dirigida a la leucemia mieloide aguda recidivante/refractaria en adultos. La compa帽铆a informa que los primeros dos pacientes han completado ensayos de seguridad de cuatro semanas con se帽ales tempranas alentadoras de eficacia.
El acuerdo incluye warrants uno a uno ejercitables a 187p por 36 meses. Tras la admisi贸n de las nuevas acciones, prevista alrededor del 7 de agosto de 2025, el n煤mero total de acciones emitidas ser谩 de 4,727,229.
Hemogenyx Pharmaceuticals (OTC:HOPHF)電� 鞝勲灥鞝� 欤检嫕 氚办爼鞚� 韱淀暣 25毵� 韺岇毚霌滊ゼ 頇曤炒頄堨溂氅�, 欤茧嫻 187韼滌姢鞐� 133,690欤检潣 氤错喌欤茧ゼ 鞁犼窚 氚滍枆頄堨姷雼堧嫟. 鞚措姅 順勳灛 鞁滌灔 臧�瓴╈棎 雽�頃� 頂勲Μ氙胳梽鞚� 鞚橂頃╇媹雼�. 欤检嫕鞚� 斓滌磮鞐� CEO 敫旊澕霐旍姮霛茧笇 靸岆摛霟棎瓴� 氚办爼霅橂┌, 鞚错泟 攴鸽姅 鞚措ゼ 鞁犼窚 韴瀽鞛� 攴鸽９鞐� 鞚挫爠頃� 鞓堨爼鞛呺媹雼�.
鞚措矆 鞛愱笀鞚� 靹膘澑 鞛皽/攵堨潙靹� 旮夓劚 瓿垬靹� 氚表槇氤戩潉 響滌爜鞙茧 頃橂姅 韨る⿺霛� 頃洂 靾橃毄觳� T靹疙彫 旃橂鞝滌澑 HG-CT-1鞚� 1靸� 鞛勳儊 鞁滍棙 歆�靻嶌潉 歆�鞗愴暊 瓴冹瀰雼堧嫟. 須岇偓電� 觳� 霊� 頇橃瀽臧� 4欤缄皠鞚� 鞎堨爠靹� 鞁滍棙鞚� 毵堨长鞙茧┌ 齑堦赴 須姤 歆曧泟臧� 瓿犽鞝侅澊霛缄碃 氤搓碃頄堨姷雼堧嫟.
鞚措矆 瓯半灅鞐愲姅 36臧滌洈 霃欖晥 頄夓偓 臧�電ロ暅 欤茧嫻 187韼滌姢鞚� 1雽�1 鞗岆煱韸戈皜 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞁犼窚 欤检嫕 靸侅灔鞚� 2025雲� 8鞗� 7鞚缄步鞙茧 鞓堨儊霅橂┌, 齑� 氚滍枆 欤检嫕 靾橂姅 4,727,229欤�臧� 霅� 瓴冹瀰雼堧嫟.
Hemogenyx Pharmaceuticals (OTC:HOPHF) a lev茅 250 000 拢 via un placement strat茅gique d'actions, 茅mettant 133 690 nouvelles actions ordinaires 脿 187p par action, repr茅sentant une prime par rapport au cours actuel du march茅. Les actions seront initialement attribu茅es au PDG Vladislav Sandler, qui les transf茅rera ensuite 脿 un groupe de nouveaux investisseurs.
Ce financement soutiendra la poursuite des essais cliniques de phase I pour HG-CT-1, leur th茅rapie par cellules T 脿 r茅cepteur antig茅nique chim茅rique ciblant la leuc茅mie my茅lo茂de aigu毛 r茅cidivante/r茅fractaire chez l'adulte. La soci茅t茅 rapporte que les deux premiers patients ont termin茅 les essais de s茅curit茅 de quatre semaines avec des signes pr茅coces d'efficacit茅 encourageants.
L'accord comprend des bons de souscription un pour un exer莽ables 脿 187p pendant 36 mois. Lors de l'admission des nouvelles actions, pr茅vue aux alentours du 7 ao没t 2025, le nombre total d'actions 茅mises sera de 4 727 229.
Hemogenyx Pharmaceuticals (OTC:HOPHF) hat durch eine strategische Aktienplatzierung 250.000 拢 eingenommen und dabei 133.690 neue Stammaktien zu je 187 Pence ausgegeben, was einen Aufschlag auf den aktuellen Marktpreis darstellt. Die Aktien werden zun盲chst dem CEO Vladislav Sandler zugeteilt, der sie anschlie脽end an eine Gruppe neuer Investoren 眉bertragen wird.
Die Finanzierung unterst眉tzt die Fortsetzung der Phase-I-Studien f眉r HG-CT-1, ihre chim盲re Antigenrezeptor-T-Zelltherapie zur Behandlung von rezidivierender/refrakt盲rer akuter myeloischer Leuk盲mie bei Erwachsenen. Das Unternehmen berichtet, dass die ersten beiden Patienten die vierw枚chigen Sicherheitstests abgeschlossen haben und ermutigende erste Anzeichen f眉r Wirksamkeit gezeigt wurden.
Der Deal umfasst Ein-zu-eins-Warrants, die zu 187 Pence f眉r 36 Monate aus眉bbar sind. Mit der Zulassung der neuen Aktien, die voraussichtlich um den 7. August 2025 erfolgt, wird die Gesamtzahl der ausgegebenen Aktien 4.727.229 betragen.
- Successful fundraising of 拢250,000 at a premium to market price
- Positive early efficacy signs from first two patients in Phase I trials
- Successful completion of four-week safety trials for HG-CT-1
- Additional potential funding through warrant exercise at 187p per share
- Small fundraising amount may require additional capital raises
- Complex share issuance structure required due to prospectus regulations
- Warrant exercise price reset clause could lead to potential dilution
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Secures
LONDON, UK / / July 29, 2025 /
Introduction
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised gross proceeds of
The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ("R/R AML"). As shareholders will be aware, the first two patients have now been treated with HG-CT-1 with the four-week safety trials successfully completed and with encouraging early signs of efficacity.
Issuance of the New Ordinary Shares
The Company is currently unable to issue and admit New Ordinary Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus.
Consequently, this fundraise involves the agreement by Vladislav Sandler, CEO and director of the Company, to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.
Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to a small group of individual investors who made an approach wishing to make a new investment in the Company; they will acquire the Subscription Shares from Mr Sandler at the price of 187p per share.
Warrants
Concurrent with the purchase of the New Ordinary Shares, the new investor group will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 187p ("Exercise Price"), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price.
Total Voting Rights
Application will be made for the 133,690 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to theFCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 7 August 2025 ("Admission").
Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 4,727,229.
鈥婽he above figure of 4,727,229 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company will keep the market informed of future developments as trials proceed.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are pleased to have attracted funding from this group of investors at a premium to the current price - this reflects their confidence in the progress made by the Company to date and in the long-term prospects of Hemogenyx. The fact that the raise was completed at a premium to the market price demonstrates this confidence and shows that they see considerable upside potential in our share price as we advance HG-CT-1 through clinical development. ."
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Director's Dealing Notification
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||
a) | Name | Vladislav Sandler | ||||||||
2. | Reason for the Notification | |||||||||
a) | Position/status | PDMR | ||||||||
b) | Initial notification / Amendment | Initial notification | ||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | Hemogenyx Pharmaceuticals plc | ||||||||
b) | LEI | 2138008L93GYU5GN6179 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of | ||||||||
Identification Code | GB00BQVXM815 | |||||||||
b) | Nature of the transaction | Off Market Allotment | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information: Aggregated volume Price | 133,690 Ordinary Shares 187 pence per Ordinary Share | ||||||||
e) | Date of the transaction | 29 July 2025 | ||||||||
f) | Place of the transaction | London | ||||||||
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City .
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit .
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original on ACCESS Newswire
FAQ
How much did Hemogenyx Pharmaceuticals (HOPHF) raise in the July 2025 placement?
What is the current status of Hemogenyx's HG-CT-1 clinical trials?
What are the terms of the warrants issued with Hemogenyx's July 2025 placement?
How many shares will Hemogenyx Pharmaceuticals have outstanding after the July 2025 placement?
What will Hemogenyx use the proceeds from the July 2025 placement for?
